LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Guardant Health Inc

Geschlossen

BrancheGesundheitswesen

40.68 0.74

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

39.97

Max

41.03

Schlüsselkennzahlen

By Trading Economics

Einkommen

16M

-95M

Verkäufe

1.7M

203M

EPS

-0.49

Gewinnspanne

-46.768

Angestellte

1,999

EBITDA

-12M

-111M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+46.83% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-762M

5.2B

Vorheriger Eröffnungskurs

39.94

Vorheriger Schlusskurs

40.68

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Guardant Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Mai 2025, 19:39 UTC

Wichtige Markttreiber

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16. Mai 2025, 23:18 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16. Mai 2025, 22:30 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- Update

16. Mai 2025, 21:56 UTC

Market Talk

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16. Mai 2025, 21:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. Mai 2025, 21:54 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- WSJ

16. Mai 2025, 21:22 UTC

Market Talk

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16. Mai 2025, 21:17 UTC

Market Talk

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16. Mai 2025, 21:17 UTC

Top News

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16. Mai 2025, 21:05 UTC

Market Talk

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16. Mai 2025, 20:55 UTC

Akquisitionen, Fusionen, Übernahmen

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16. Mai 2025, 20:50 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

16. Mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. Mai 2025, 20:37 UTC

Top News

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16. Mai 2025, 20:33 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16. Mai 2025, 20:30 UTC

Akquisitionen, Fusionen, Übernahmen

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16. Mai 2025, 20:18 UTC

Top News

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16. Mai 2025, 20:16 UTC

Top News

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16. Mai 2025, 20:15 UTC

Ergebnisse

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16. Mai 2025, 20:11 UTC

Akquisitionen, Fusionen, Übernahmen

Henry Schein: William K. Daniel Joins Board

16. Mai 2025, 20:10 UTC

Akquisitionen, Fusionen, Übernahmen

Henry Schein: Strategic Investment by KKR Completed

16. Mai 2025, 20:05 UTC

Akquisitionen, Fusionen, Übernahmen

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16. Mai 2025, 19:38 UTC

Market Talk

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16. Mai 2025, 19:07 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

16. Mai 2025, 18:51 UTC

Top News

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16. Mai 2025, 18:41 UTC

Akquisitionen, Fusionen, Übernahmen

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16. Mai 2025, 18:37 UTC

Market Talk

Gold Futures End Week on Negative Note -- Market Talk

16. Mai 2025, 18:35 UTC

Top News

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16. Mai 2025, 18:32 UTC

Top News

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16. Mai 2025, 18:28 UTC

Market Talk

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Peer-Vergleich

Kursveränderung

Guardant Health Inc Prognose

Kursziel

By TipRanks

46.83% Vorteil

12-Monats-Prognose

Durchschnitt 59.79 USD  46.83%

Hoch 70 USD

Tief 52 USD

Basierend auf 20 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Guardant Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

20 ratings

20

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

38.86 / 47.41Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.